In addition, a recent review summarized the evidence for the broad cardiovascular and metabolic benefits of GLP1-RAs (lixisenatide, exenatide, liraglutide, semaglutide, albiglutide, and dulaglutide) in nondiabetic patients with a variety of conditions, including PCOS [58]. The gene discussed is GCG; the disease is polycystic ovary syndrome.